Upcoming event

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)

A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk

SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC)

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426

Clinical outcomes of checkpoint inhibitors in metastatic non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with variant features

Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era

Intrarenal renin-angiotensin system in hypertensive patients with localized kidney cancer

The serum level of the components of the renin-angiotensin system correlates with its tumor tissue expression in kidney cancer patients

Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer

Urologic Oncology: Seminars and Original Investigations, Volume 38, Issue 5, May 2020, Pages 521-525

Hypertension and cardiovascular morbidity following surgery for kidney cancer

European Urology Oncology, Volume 3, Issue 2, April 2020, Pages 209-215

First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium

European Urology, Volume 76, Issue 6, December 2020, Pages 861-867

Next